Skip to search formSkip to main contentSkip to account menu

obinutuzumab

Known as: Afutuzumab, Immunoglobulin G1, anti-(human CD20 (antigen)) (human-mouse monoclonal GA101 heavy chain), disulfide with human-mouse monoclonal GA101 KAPPA-chain, dimer, huMAB(CD20) 
A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Afutuzumab, a third generation type II anti-CD20… 
National Institutes of Health

Related topics

Related topics

11 relations
40 ML obinutuzumab 25 MG/ML Injection [Gazyva]Antibody-Dependent Cellular CytotoxicityB-LymphocytesCytotoxic T-Lymphocytes

Broader (2)

Antibodies, Monoclonal, HumanizedAntineoplastic Agents

Narrower (3)

GA 101GazyvaRO 5072759

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax.
8006Background: Venetoclax (Ven)-Obinutuzumab (O) is approved for chronic lymphocytic leukemia (CLL) achieving frequent… 
2018
2018
Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia
BACKGROUND Development of targeted therapies for CLL including the anti-CD20 monoclonal antibody obinutuzumab (OBIN), Bruton's… 
2017
2017
Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia
2016
2016
Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study
Background: Minimal residual disease (MRD) status reflects treatment efficacy and may predict prognosis after first-line therapy… 
Review
2015
Review
2015
Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.
2014
2014
Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11…
Introduction: Chemoimmunotherapy with the glycoengineered type II anti-CD20 antibody obinutuzumab plus the alkylating drug… 
2013
2013
Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities…
Introduction CLL11 is a large randomized phase 3 trial investigating first-line chemoimmunotherapy in CLL patients with… 
Review
2013
Review
2013
Safety and Efficacy Of Obinutuzumab (GA101) Plus CHOP Chemotherapy In First-Line Advanced Diffuse Large B-Cell Lymphoma: Results From The Phase 2 Gather Study (GAO4915g)
Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and has an aggressive natural history… 
Review
2011
Review
2011
Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study
Abstract 269 Background: GA101 is the first type II glycoengineered CD20 monoclonal antibody in phase II/III clinical trials for… 
2011
2011
Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results From a Phase II Study (BO20999),
Abstract 3655 Obinutuzumab (GA101) is a type II glycoengineered, humanized anti-CD20 monoclonal antibody that has increased… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)